Former Fresenius-Kabi China President joins Oculis

Oculis, a Swiss biopharmaceutical company, has announced the appointment of Webb Ding as global Chief Operating Officer and General Manager, China, with effect from February 1, 2022. Ding brings vast healthcare leadership experience, with a specific focus on China market. Ding joins the Oculis Executive Leadership Team, where his decades of experience in multinational pharmaceutical company operations will help drive the company forward as it continues to develop its product pipeline and scale globally. The appointment of Ding also further strengthens Oculis’ development efforts in the Greater China region, following the establishment of a Hong Kong presence earlier in the year. Ding has more than 25 years of experience in general management, successful go-to-market strategies, business development and licensing, and operational excellence across multiple healthcare segments. He joins Oculis from Fresenius-Kabi, one of the top 10 multinational pharmaceutical companies in China, where he served as Country President for China, building market leadership and a strong competitive portfolio. Prior to Fresenius-Kabi, Ding spent more than 10 years with Novartis in China in leadership roles of increasing responsibility, culminating in his appointment as General Manager of Novartis Vaccines Greater China and Tianyuan BioPharma. Ding was also a member of the Global

Executive Committee of Novartis Vaccines.